Familial Cancer

, Volume 12, Issue 3, pp 529–535

Mutation screening in a Norwegian cohort with pheochromocytoma

  • Wenche Sjursen
  • Henrik Halvorsen
  • Eva Hofsli
  • Siri Bachke
  • Åsa Berge
  • Lars F. Engebretsen
  • Sture E. Falkmer
  • Ursula G. Falkmer
  • Jan E. Varhaug
Original Article

Abstract

Pheochromocytomas (PHEOs) are neuroendocrine tumours, originating from chromaffin cells in the adrenal medulla. They are either sporadic or hereditary. It is important to identify the hereditary cases, so that patients and relatives with germline mutations can be offered regular surveillance. The objective of this study was the detection of pathogenic germline mutations in a cohort of Norwegian PHEO patients. Blood samples and/or formalin-fixed, paraffin-embedded tissue specimens, were collected from 60 patients who were operated upon between 1986 and 2004 at two university hospitals in Norway. DNA mutation analyses were performed successfully in the 42 blood samples and in one of the paraffin-embedded tissue specimen in VHL, RET, SDHB, SDHC, SDHD and NF1. In all, 32 different DNA variants were observed, of which 8 were classified as pathogenic (19 %), or possibly pathogenic; three in NF1, two in RET and VHL and one in SDHB. Two variants were observed in one patient, one in SDHB and one in NF1. Three of these variants are, to the best of our knowledge, new ones; two in NF1 [c.950_51insGCTGA, (p.Glu318LeufsX59) and c.1588G > A, (p.Val530Ile)] and one in VHL (c.308C > T, p.Pro103Leu). In conclusion the overall incidence of germline mutations in genes associated with familial PHEO was found to be of the same order of magnitude in the present Norwegian series as in those from other countries. Two new NF1 variants and one new VHL gene variant were detected.

Keywords

Pheochromocytoma Germ line mutations RET VHL SDHB SDHC SDHD NF1 

Abbreviations

PHEO

Pheochromocytoma

NET

Neuroendocrine tumour

NF1

Neurofibromatosis type 1

SDH

Succinate dehydrogenase

VHL

von Hippel Lindau

Supplementary material

10689_2013_9608_MOESM1_ESM.pdf (118 kb)
Supplementary material 1 (PDF 118 kb)

References

  1. 1.
    Pacak K, Eisenhofer G, Ahlman H, Bornstein SR, Gimenez-Roqueplo AP, Grossman AB, Kimura N, Mannelli M, McNicol AM, Tischler AS (2007) Pheochromocytoma: recommendations for clinical practice from the first international symposium October 2005. Nat Clin Pract Endocrinol Metab 3(2):92–102. doi:10.1038/ncpendmet0396 PubMedCrossRefGoogle Scholar
  2. 2.
    Parenti G, Zampetti B, Rapizzi E, Ercolino T, Giache V, Mannelli M (2012) Updated and new perspectives on diagnosis, prognosis, and therapy of malignant pheochromocytoma/paraganglioma. J Oncol 2012:872713. doi:10.1155/2012/872713 PubMedCrossRefGoogle Scholar
  3. 3.
    Bulow B, Jansson S, Juhlin C, Steen L, Thoren M, Wahrenberg H, Valdemarsson S, Wangberg B, Ahren B (2006) Adrenal incidentaloma—follow-up results from a Swedish prospective study. Eur J Endocrinol 154(3):419–423. doi:10.1530/eje.1.02110 PubMedCrossRefGoogle Scholar
  4. 4.
    Sutton MG, Sheps SG, Lie JT (1981) Prevalence of clinically unsuspected pheochromocytoma. Review of a 50-year autopsy series. Mayo Clin Proc 56(6):354–360PubMedGoogle Scholar
  5. 5.
    Platts JK, Drew PJ, Harvey JN (1995) Death from phaeochromocytoma: lessons from a post-mortem survey. J R Coll Physicians Lond 29(4):299–306PubMedGoogle Scholar
  6. 6.
    Neumann HP, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G, Schipper J, Klisch J, Altehoefer C, Zerres K, Januszewicz A, Eng C, Smith WM, Munk R, Manz T, Glaesker S, Apel TW, Treier M, Reineke M, Walz MK, Hoang-Vu C, Brauckhoff M, Klein-Franke A, Klose P, Schmidt H, Maier-Woelfle M, Peczkowska M, Szmigielski C (2002) Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 346(19):1459–1466. doi:10.1056/NEJMoa020152 PubMedCrossRefGoogle Scholar
  7. 7.
    Korpershoek E, Favier J, Gaal J, Burnichon N, van Gessel B, Oudijk L, Badoual C, Gadessaud N, Venisse A, Bayley JP, van Dooren MF, de Herder WW, Tissier F, Plouin PF, van Nederveen FH, Dinjens WN, Gimenez-Roqueplo AP, de Krijger RR (2011) SDHA immunohistochemistry detects germline SDHA gene mutations in apparently sporadic paragangliomas and pheochromocytomas. J Clin Endocrinol Metab 96(9):E1472–E1476. doi:10.1210/jc.2011-1043 PubMedCrossRefGoogle Scholar
  8. 8.
    Bayley JP, Kunst HP, Cascon A, Sampietro ML, Gaal J, Korpershoek E, Hinojar-Gutierrez A, Timmers HJ, Hoefsloot LH, Hermsen MA, Suarez C, Hussain AK, Vriends AH, Hes FJ, Jansen JC, Tops CM, Corssmit EP, de Knijff P, Lenders JW, Cremers CW, Devilee P, Dinjens WN, de Krijger RR, Robledo M (2010) SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma. Lancet Oncol 11(4):366–372. doi:10.1016/S1470-2045(10)70007-3 PubMedCrossRefGoogle Scholar
  9. 9.
    Yao L, Schiavi F, Cascon A, Qin Y, Inglada-Perez L, King EE, Toledo RA, Ercolino T, Rapizzi E, Ricketts CJ, Mori L, Giacche M, Mendola A, Taschin E, Boaretto F, Loli P, Iacobone M, Rossi GP, Biondi B, Lima-Junior JV, Kater CE, Bex M, Vikkula M, Grossman AB, Gruber SB, Barontini M, Persu A, Castellano M, Toledo SP, Maher ER, Mannelli M, Opocher G, Robledo M, Dahia PL Spectrum and prevalence of FP/TMEM127 gene mutations in pheochromocytomas and paragangliomas. JAMA 304:23 2611–2619. doi:10.1001/jama.2010.1830
  10. 10.
    Comino-Mendez I, Gracia-Aznarez FJ, Schiavi F, Landa I, Leandro-Garcia LJ, Leton R, Honrado E, Ramos-Medina R, Caronia D, Pita G, Gomez-Grana A, de Cubas AA, Inglada-Perez L, Maliszewska A, Taschin E, Bobisse S, Pica G, Loli P, Hernandez-Lavado R, Diaz JA, Gomez-Morales M, Gonzalez-Neira A, Roncador G, Rodriguez-Antona C, Benitez J, Mannelli M, Opocher G, Robledo M, Cascon A (2011) Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat Genet 43(7):663–667. doi:10.1038/ng.861 PubMedCrossRefGoogle Scholar
  11. 11.
    Opocher G, Schiavi F (2010) Genetics of pheochromocytomas and paragangliomas. Best Pract Res Clin Endocrinol Metab 24(6):943–956. doi:10.1016/j.beem.2010.05.001 PubMedCrossRefGoogle Scholar
  12. 12.
    Gimm O, DeMicco C, Perren A, Giammarile F, Walz MK, Brunaud L (2012) Malignant pheochromocytomas and paragangliomas: a diagnostic challenge. Langenbecks Arch Surg 397(2):155–177. doi:10.1007/s00423-011-0880-x PubMedCrossRefGoogle Scholar
  13. 13.
    Gimenez-Roqueplo AP, Favier J, Rustin P, Rieubland C, Crespin M, Nau V, Khau Van Kien P, Corvol P, Plouin PF, Jeunemaitre X (2003) Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res 63(17):5615–5621PubMedGoogle Scholar
  14. 14.
    Gill AJ, Benn DE, Chou A, Clarkson A, Muljono A, Meyer-Rochow GY, Richardson AL, Sidhu SB, Robinson BG, Clifton-Bligh RJ (2010) Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes. Hum Pathol 41(6):805–814. doi:10.1016/j.humpath.2009.12.005 PubMedCrossRefGoogle Scholar
  15. 15.
    Kytola S, Nord B, Elder EE, Carling T, Kjellman M, Cedermark B, Juhlin C, Hoog A, Isola J, Larsson C (2002) Alterations of the SDHD gene locus in midgut carcinoids, Merkel cell carcinomas, pheochromocytomas, and abdominal paragangliomas. Genes Chromosomes Cancer 34(3):325–332. doi:10.1002/gcc.10081 PubMedCrossRefGoogle Scholar
  16. 16.
    Cascon A, Ruiz-Llorente S, Cebrian A, Leton R, Telleria D, Benitez J, Robledo M (2003) G12S and H50R variations are polymorphisms in the SDHD gene. Genes Chromosomes Cancer 37(2):220–221. doi:10.1002/gcc.10212 PubMedCrossRefGoogle Scholar
  17. 17.
    Lima J, Maximo V, Soares P, Sobrinho-Simoes M (2003) Alterations of the SDHD gene locus in midgut carcinoids. Genes Chromosomes Cancer 36(4):424. doi:10.1002/gcc.10147 PubMedCrossRefGoogle Scholar
  18. 18.
    Gimenez-Roqueplo AP, Lehnert H, Mannelli M, Neumann H, Opocher G, Maher ER, Plouin PF (2006) Phaeochromocytoma, new genes and screening strategies. Clin Endocrinol (Oxf) 65(6):699–705. doi:10.1111/j.1365-2265.2006.02714.x CrossRefGoogle Scholar
  19. 19.
    Kim L, Holland AJ, Srinivasan S, Cowell CT, Benn DE, Robinson BG (2008) Paediatric bilateral adrenal phaeochromocytomas in association with a novel mutation in the von Hippel Lindau gene. J Paediatr Child Health 44(9):514–516. doi:10.1111/j.1440-1754.2008.01360.x PubMedCrossRefGoogle Scholar
  20. 20.
    Dollfus H, Massin P, Taupin P, Nemeth C, Amara S, Giraud S, Beroud C, Dureau P, Gaudric A, Landais P, Richard S (2002) Retinal hemangioblastoma in von Hippel-Lindau disease: a clinical and molecular study. Invest Ophthalmol Vis Sci 43(9):3067–3074PubMedGoogle Scholar
  21. 21.
    Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399(6733):271–275. doi:10.1038/20459 PubMedCrossRefGoogle Scholar
  22. 22.
    Eng C, Crossey PA, Mulligan LM, Healey CS, Houghton C, Prowse A, Chew SL, Dahia PL, O’Riordan JL, Toledo SP et al (1995) Mutations in the RET proto-oncogene and the von Hippel-Lindau disease tumour suppressor gene in sporadic and syndromic phaeochromocytomas. J Med Genet 32(12):934–937PubMedCrossRefGoogle Scholar
  23. 23.
    Hoffman MA, Ohh M, Yang H, Klco JM, Ivan M, Kaelin WG Jr (2001) von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum Mol Genet 10(10):1019–1027PubMedCrossRefGoogle Scholar
  24. 24.
    Maertens O, Brems H, Vandesompele J, De Raedt T, Heyns I, Rosenbaum T, De Schepper S, De Paepe A, Mortier G, Janssens S, Speleman F, Legius E, Messiaen L (2006) Comprehensive NF1 screening on cultured Schwann cells from neurofibromas. Hum Mutat 27(10):1030–1040. doi:10.1002/humu.20389 PubMedCrossRefGoogle Scholar
  25. 25.
    Bausch B, Borozdin W, Mautner VF, Hoffmann MM, Boehm D, Robledo M, Cascon A, Harenberg T, Schiavi F, Pawlu C, Peczkowska M, Letizia C, Calvieri S, Arnaldi G, Klingenberg-Noftz RD, Reisch N, Fassina A, Brunaud L, Walter MA, Mannelli M, MacGregor G, Palazzo FF, Barontini M, Walz MK, Kremens B, Brabant G, Pfaffle R, Koschker AC, Lohoefner F, Mohaupt M, Gimm O, Jarzab B, McWhinney SR, Opocher G, Januszewicz A, Kohlhase J, Eng C, Neumann HP (2007) Germline NF1 mutational spectra and loss-of-heterozygosity analyses in patients with pheochromocytoma and neurofibromatosis type 1. J Clin Endocrinol Metab 92(7):2784–2792. doi:10.1210/jc.2006-2833 PubMedCrossRefGoogle Scholar
  26. 26.
    Maynard J, Krawczak M, Upadhyaya M (1997) Characterization and significance of nine novel mutations in exon 16 of the neurofibromatosis type 1 (NF1) gene. Hum Genet 99(5):674–676PubMedCrossRefGoogle Scholar
  27. 27.
    Neumann HP, Erlic Z, Boedeker CC, Rybicki LA, Robledo M, Hermsen M, Schiavi F, Falcioni M, Kwok P, Bauters C, Lampe K, Fischer M, Edelman E, Benn DE, Robinson BG, Wiegand S, Rasp G, Stuck BA, Hoffmann MM, Sullivan M, Sevilla MA, Weiss MM, Peczkowska M, Kubaszek A, Pigny P, Ward RL, Learoyd D, Croxson M, Zabolotny D, Yaremchuk S, Draf W, Muresan M, Lorenz RR, Knipping S, Strohm M, Dyckhoff G, Matthias C, Reisch N, Preuss SF, Esser D, Walter MA, Kaftan H, Stover T, Fottner C, Gorgulla H, Malekpour M, Zarandy MM, Schipper J, Brase C, Glien A, Kuhnemund M, Koscielny S, Schwerdtfeger P, Valimaki M, Szyfter W, Finckh U, Zerres K, Cascon A, Opocher G, Ridder GJ, Januszewicz A, Suarez C, Eng C (2009) Clinical predictors for germline mutations in head and neck paraganglioma patients: cost reduction strategy in genetic diagnostic process as fall-out. Cancer Res 69(8):3650–3656. doi:10.1158/0008-5472.CAN-08-4057 PubMedCrossRefGoogle Scholar
  28. 28.
    Piccini V, Rapizzi E, Bacca A, Di Trapani G, Pulli R, Giache V, Zampetti B, Lucci-Cordisco E, Canu L, Corsini E, Faggiano A, Deiana L, Carrara D, Tantardini V, Mariotti S, Ambrosio MR, Zatelli MC, Parenti G, Colao A, Pratesi C, Bernini G, Ercolino T, Mannelli M (2012) Head and neck paragangliomas: genetic spectrum and clinical variability in 79 consecutive patients. Endocr Relat Cancer 19(2):149–155. doi:10.1530/ERC-11-0369 PubMedCrossRefGoogle Scholar
  29. 29.
    Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L et al (1993) Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363(6428):458–460. doi:10.1038/363458a0 PubMedCrossRefGoogle Scholar
  30. 30.
    Landsvater RM, Jansen RP, Hofstra RM, Buys CH, Lips CJ, Ploos van Amstel HK (1996) Mutation analysis of the RET proto-oncogene in Dutch families with MEN 2A, MEN 2B and FMTC: two novel mutations and one de novo mutation for MEN 2A. Hum Genet 97(1):11–14PubMedCrossRefGoogle Scholar
  31. 31.
    Machens A, Brauckhoff M, Holzhausen HJ, Thanh PN, Lehnert H, Dralle H (2005) Codon-specific development of pheochromocytoma in multiple endocrine neoplasia type 2. J Clin Endocrinol Metab 90(7):3999–4003. doi:10.1210/jc.2005-0064 PubMedCrossRefGoogle Scholar
  32. 32.
    Plaza-Menacho I, Burzynski GM, de Groot JW, Eggen BJ, Hofstra RM (2006) Current concepts in RET-related genetics, signaling and therapeutics. Trends Genet 22(11):627–636. doi:10.1016/j.tig.2006.09.005 PubMedCrossRefGoogle Scholar
  33. 33.
    Niemann S, Muller U (2000) Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet 26(3):268–270. doi:10.1038/81551 PubMedCrossRefGoogle Scholar
  34. 34.
    Peczkowska M, Cascon A, Prejbisz A, Kubaszek A, Cwikla BJ, Furmanek M, Erlic Z, Eng C, Januszewicz A, Neumann HP (2008) Extra-adrenal and adrenal pheochromocytomas associated with a germline SDHC mutation. Nat Clin Pract Endocrinol Metab 4(2):111–115. doi:10.1038/ncpendmet0726 PubMedCrossRefGoogle Scholar
  35. 35.
    Welander J, Soderkvist P, Gimm O (2011) Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas. Endocr Relat Cancer 18(6):R253–R276. doi:10.1530/ERC-11-0170 PubMedCrossRefGoogle Scholar
  36. 36.
    Karasek D, Shah U, Frysak Z, Stratakis C, Pacak K (2012) An update on the genetics of pheochromocytoma. J Hum Hypertens. doi:10.1038/jhh.2012.20 PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  • Wenche Sjursen
    • 1
    • 2
  • Henrik Halvorsen
    • 3
  • Eva Hofsli
    • 4
    • 5
  • Siri Bachke
    • 2
  • Åsa Berge
    • 2
  • Lars F. Engebretsen
    • 6
  • Sture E. Falkmer
    • 1
    • 2
    • 7
  • Ursula G. Falkmer
    • 4
    • 5
    • 8
  • Jan E. Varhaug
    • 3
    • 9
  1. 1.Departments of Pathology and Medical GeneticsSt Olav University HospitalTrondheimNorway
  2. 2.Department of Laboratory Medicine Children’s and Women’s HealthNorwegian University of Science and Technology (NTNU)TrondheimNorway
  3. 3.Department of Breast and Endocrine SurgeryHaukeland University HospitalBergenNorway
  4. 4.Cancer ClinicSt Olav University HospitalTrondheimNorway
  5. 5.Department of Cancer Research and Molecular MedicineNTNUTrondheimNorway
  6. 6.Center for Medical Genetics and Molecular MedicineHaukeland University HospitalBergenNorway
  7. 7.Laboratory of Clinical Pathology and CytologyJönköpingSweden
  8. 8.Oncology ClinicCounty Hospital RyhovJönköpingSweden
  9. 9.Department of Surgical SciencesUniversity of BergenBergenNorway

Personalised recommendations